Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EDNRA | P25101 | 1/20 | 0.58 |
| ▸ | NPBWR1 | P48145 | 3/20 | 0.55 |
| ▸ | PCSK9 | Q8NBP7 | 2/20 | 0.55 |
| ▸ | ERAP2 | Q6P179 | 1/20 | 0.53 |
| ▸ | KISS1R | Q969F8 | 1/20 | 0.52 |
| ▸ | CTSB | P07858 | 1/20 | 0.52 |
| ▸ | CTSK | P43235 | 1/20 | 0.52 |
| ▸ | CCNA2 | P20248 | 2/20 | 0.51 |
| ▸ | CDK2 | P24941 | 2/20 | 0.51 |
| ▸ | CCNA1 | P78396 | 2/20 | 0.51 |
| ▸ | GHSR | Q92847 | 1/20 | 0.51 |
| ▸ | TLR2 | O60603 | 2/20 | 0.51 |
| ▸ | MAGI3 | Q5TCQ9 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30093094 | 0.96 | NPBWR1 (0.58) | EDNRANPBWR1PCSK9ERAP2KISS1R | |
| SCHEMBL30092974 | 0.94 | EDNRA (0.61) | EDNRANPBWR1PCSK9ERAP2CTSB | |
| SCHEMBL30093140 | 0.94 | RXFP1 (0.57) | EDNRANPBWR1PCSK9KISS1R | |
| SCHEMBL30093061 | 0.94 | RXFP1 (0.57) | EDNRANPBWR1PCSK9KISS1R | |
| SCHEMBL30093112 | 0.94 | RXFP1 (0.57) | EDNRANPBWR1PCSK9KISS1R | |
| SCHEMBL30092976 | 0.94 | RXFP1 (0.57) | EDNRANPBWR1PCSK9KISS1R | |
| SCHEMBL30092924 | 0.94 | RXFP1 (0.57) | EDNRANPBWR1PCSK9KISS1R | |
| SCHEMBL30093006 | 0.94 | EDNRA (0.61) | EDNRANPBWR1PCSK9ERAP2CTSB | |
| SCHEMBL29706172 | 0.93 | NPBWR1 (0.56) | EDNRANPBWR1PCSK9KISS1RCTSB | |
| SCHEMBL30977971 | 0.93 | NPBWR1 (0.59) | EDNRANPBWR1KISS1RGHSR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230287044-A1 | NOVEL ANTIBACTERIAL PEPTIDE AND USE THEREOF | ANYGEN CO., LTD. (KR) | 2023-09-14 | — | — | US | claimed |
| EP-4129064-A1 | NOVEL ANTIBACTERIAL PEPTIDE AND USE THEREOF | Anygen Co., Ltd. (KR) | 2023-02-08 | — | — | EP | claimed |
| US-20230287044-A1 | NOVEL ANTIBACTERIAL PEPTIDE AND USE THEREOF | ANYGEN CO., LTD. (KR) | 2023-09-14 | — | — | US | disclosed |
| EP-4129064-A1 | NOVEL ANTIBACTERIAL PEPTIDE AND USE THEREOF | Anygen Co., Ltd. (KR) | 2023-02-08 | — | — | EP | disclosed |
| CN-115397836-A | Novel antibacterial peptide and application thereof | 安尼根有限公司 | 2022-11-25 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230287044-A1 | NOVEL ANTIBACTERIAL PEPTIDE AND USE THEREOF | VIP, CUTA, LNPEP | EDNRA 3344/4885NPBWR1 61/4885PCSK9 575/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.